Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy.
Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C. Treatment lasted for one year and patients were evaluated after a mean follow-up of 35 to 47 months if progression had not occurred. Mitomycin C was superior in reducing the recurrence rate. Progressive disease was observed in 17 patients regardless of therapy but in all patients DNA aneuploidy could be identified at a risk factor.
Gustafson
H
H
Department of Urology, Danderyd Hospital, Stockholm, Sweden.
Wijkström
H
H
Nyman
C
C
Brolin
J
J
Borgström
E
E
Tribukait
B
B
D000283:Administration, Intravesical; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000235:genetics*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local; D011003:Ploidies; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery
D004273:DNA, Neoplasm; D016685:Mitomycin; D004317:Doxorubicin